HK1201843A1 - 抗聚泛素抗體及使用方法 - Google Patents

抗聚泛素抗體及使用方法

Info

Publication number
HK1201843A1
HK1201843A1 HK15101412.1A HK15101412A HK1201843A1 HK 1201843 A1 HK1201843 A1 HK 1201843A1 HK 15101412 A HK15101412 A HK 15101412A HK 1201843 A1 HK1201843 A1 HK 1201843A1
Authority
HK
Hong Kong
Prior art keywords
methods
polyubiquitin antibodies
polyubiquitin
antibodies
Prior art date
Application number
HK15101412.1A
Other languages
English (en)
Inventor
Robert F Kelley
Marissa L Matsumoto
Vishva Dixit
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1201843A1 publication Critical patent/HK1201843A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK15101412.1A 2011-08-05 2015-02-09 抗聚泛素抗體及使用方法 HK1201843A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515729P 2011-08-05 2011-08-05
PCT/US2012/049771 WO2013022848A1 (en) 2011-08-05 2012-08-06 Anti-polyubiquitin antibodies and methods of use

Publications (1)

Publication Number Publication Date
HK1201843A1 true HK1201843A1 (zh) 2015-09-11

Family

ID=47668865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101412.1A HK1201843A1 (zh) 2011-08-05 2015-02-09 抗聚泛素抗體及使用方法

Country Status (10)

Country Link
US (4) US9321844B2 (zh)
EP (1) EP2739651B1 (zh)
JP (2) JP6411212B2 (zh)
KR (1) KR20140054177A (zh)
CN (1) CN104011078B (zh)
BR (1) BR112014002716A2 (zh)
HK (1) HK1201843A1 (zh)
MX (1) MX2014001238A (zh)
RU (1) RU2630637C2 (zh)
WO (1) WO2013022848A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2325208B1 (en) 2005-12-15 2017-09-20 Genentech, Inc. Polyubiquitin antibodies
EP2247617B1 (en) 2008-01-18 2013-02-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP2558496B1 (en) * 2010-04-15 2018-07-25 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
MX2014001238A (es) 2011-08-05 2014-09-22 Genentech Inc Anticuerpos contra poliubiquitina y métodos de uso.
KR102233349B1 (ko) * 2013-03-15 2021-03-31 에이씨 이뮨 에스.에이. 항-타우(tau) 항체 및 사용 방법
WO2017000050A1 (en) 2015-06-29 2017-01-05 L'oreal Oil controlling sunscreen composition
IL257565B1 (en) 2015-09-23 2024-04-01 Genentech Inc Improved variants of anti-VEGF antibodies
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3475298A1 (en) * 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
JP2020507577A (ja) * 2017-02-10 2020-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｐｓｍａ、ｎｋｇ２ｄおよびｃｄ１６に結合するタンパク質
KR20220024460A (ko) * 2019-06-11 2022-03-03 안틀라 테라퓨틱스 아이엔씨. 다가 fzd 및 wnt 결합 분자 및 이의 용도
JP2023536630A (ja) * 2020-08-04 2023-08-28 エグゼリクシス， インコーポレイテッド Ｐｄ－ｌ１結合性作用剤およびその使用
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CN117447610B (zh) * 2023-10-27 2024-04-26 重庆天科雅生物科技有限公司 一种嵌合抗原受体（car）及其在制备抗肿瘤药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07238096A (ja) 1994-02-25 1995-09-12 S R L:Kk 抗ポリユビキチン・モノクローナル抗体およびポリユビキチンの測定方法
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1745131A2 (en) 2004-05-12 2007-01-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. METHOD TO INDUCE RNAi IN PROKARYOTIC ORGANISMS
AU2006282853B2 (en) 2005-08-25 2011-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis
EP2325208B1 (en) 2005-12-15 2017-09-20 Genentech, Inc. Polyubiquitin antibodies
EP1808493A3 (en) 2006-01-13 2007-11-21 Hybrigenics S.A. Substrates and methods for assaying deubiquitinating enzymes activity
WO2008121813A2 (en) 2007-03-30 2008-10-09 Genentech, Inc. Modulation of cytokine production
EP2247617B1 (en) * 2008-01-18 2013-02-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
EP2558496B1 (en) 2010-04-15 2018-07-25 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
MX2014001238A (es) 2011-08-05 2014-09-22 Genentech Inc Anticuerpos contra poliubiquitina y métodos de uso.

Also Published As

Publication number Publication date
RU2014108309A (ru) 2015-09-10
JP2017200484A (ja) 2017-11-09
JP6411212B2 (ja) 2018-10-24
EP2739651B1 (en) 2019-02-20
MX2014001238A (es) 2014-09-22
EP2739651A4 (en) 2015-02-25
US10738106B2 (en) 2020-08-11
US20160304591A1 (en) 2016-10-20
CN104011078A (zh) 2014-08-27
BR112014002716A2 (pt) 2017-06-13
JP2014531894A (ja) 2014-12-04
KR20140054177A (ko) 2014-05-08
WO2013022848A1 (en) 2013-02-14
US11597761B2 (en) 2023-03-07
CN104011078B (zh) 2016-11-09
US20210017260A1 (en) 2021-01-21
US9321844B2 (en) 2016-04-26
US20130058955A1 (en) 2013-03-07
RU2630637C2 (ru) 2017-09-11
US20230348581A1 (en) 2023-11-02
EP2739651A1 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
HK1255608A1 (zh) 抗htra1抗體及使用方法
HK1212256A1 (zh) 抗- 抗體及相關使用方法
HK1205517A1 (zh) 抗體及使用方法
HK1201843A1 (zh) 抗聚泛素抗體及使用方法
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2771694A4 (en) MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
EP2734234A4 (en) ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2558496A4 (en) ANTIBODIES TO POLYUBIQUITINE AND METHOD FOR THEIR USE
HK1209432A1 (zh) 抗鋸齒蛋白抗體及使用方法
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2663330A4 (en) ANTIBODIES TO TLR4 AND METHOD FOR THEIR USE
HK1201537A1 (zh) 抗- 抗體和使用方法
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2670245A4 (en) ALPHA-CÉTOHÉTÉROCYCLES AND METHODS OF MAKING AND USING THEM
EP2670436A4 (en) FOXC1 ANTIBODIES AND METHOD FOR THEIR USE
HK1184173A1 (zh) 抗- 抗體和使用方法